ArticleNature communications2021
Modeling serological testing to inform relaxation of social distancing for COVID-19 control.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Data-driven strategies for model-informed decision-making during the COVID-19 pandemic: a systematic review.BMJ open · 2026Pooled it
- Pooled it
- Quantifying indirect and direct vaccination effects arising in the SIR model.Journal of the Royal Society, Interface · 2024Article
- Optimal Adaptive Testing for Epidemic Control: Combining Molecular and Serology Tests.Automatica : the journal of IFAC, the International Federation of Automatic Control · 2024Article
- Development of multi-scale indices of human mobility restriction during the COVID-19 based on air quality from local and global NOiScience · 2023Article
- Open data for COVID-19 policy analysis and mapping.Scientific data · 2023Article
- Performance Evaluation of RapiSure (EDGC) COVID-19 S1 RBD IgG/Neutralizing Ab Test for the Rapid Detection of SARS-CoV-2 Antibodies.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Article
- Germany's fourth COVID-19 wave was mainly driven by the unvaccinated.Communications medicine · 2022Article
- Disease-dependent interaction policies to support health and economic outcomes during the COVID-19 epidemic.iScience · 2021Article
- SARS-CoV-2 Viral and Serological Testing When College Campuses Reopen: Some Practical Considerations.Disaster medicine and public health preparedness · 2021Article
- Strategies to exiting the COVID-19 lockdown for workplace and school: A scoping review.Safety science · 2021Article
- Serological determinants of COVID-19.Biology direct · 2020Article
- Diagnostic performances and thresholds: The key to harmonization in serological SARS-CoV-2 assays?Clinica chimica acta; international journal of clinical chemistry · 2020Article
- Disease-dependent interaction policies to support health and economic outcomes during the COVID-19 epidemic.medRxiv : the preprint server for health sciences · 2020Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Serological testing remains a passive component of the public health response to the COVID-19 pandemic. Using a transmission model, we examine how serological testing could have enabled seropositive individuals to increase their relative levels of social interaction while offsetting transmission risks. We simulate widespread serological testing in New York City, South Florida, and Washington Puget Sound and assume seropositive individuals partially restore their social contacts. Compared to no intervention, our model suggests that widespread serological testing starting in late 2020 would have averted approximately 3300 deaths in New York City, 1400 deaths in South Florida and 11,000 deaths in Washington State by June 2021. In all sites, serological testing blunted subsequent waves of transmission. Findings demonstrate the potential benefit of widespread serological testing, had it been implemented in the pre-vaccine era, and remain relevant now amid the potential for emergence of new variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.